[팜뉴스=최선재 기자] Boryung (formerly Boryung Pharmaceutical) and HK Innoen announced on the 20th that they have decided to jointly sell their popular new drugs Kanarb (ingredient name: pimasartan) and K-Cap (ingredient name: tegoprazan), respectively.
Accordingly, Boryeong and HK InnoN will jointly conduct domestic sales and marketing for Kanarb and K-Cap starting from January next year. Boryeong and HK Innoen jointly sell ‘K-Cap Tablets’ and ‘K-Cap Orally Disintegrating Tablets’, and HK Innoen jointly sells 4 types of Kanarb product line (Kanarb, Ducaro, Ducarb, and Ducarb Plus) with Boryung.
Kanarb and K-Cap are both blockbuster products with annual sales of more than KRW 100 billion, and are representative products of K-new drugs.
This decision by both companies is significant as it is the first case of collaboration between companies that created a blockbuster new drug. Boryung and HK InnoN plan to share the sales and marketing capabilities they have accumulated for blood circulation and digestion treatments, where each has strengths, and create a new turning point in strengthening the market dominance and growth of both products . As Boryung was able to expand its product portfolio to the gastroenterology market and HK InnoN to the circulatory system market, the business area also expanded.
Kanarb is Korea’s first new drug for high blood pressure developed by Boryung. Kanarb, the 15th domestically produced new drug, has continued to release combination drugs and wider treatment options to treat not only patients with varying levels of high blood pressure but also related diseases. Kanarb’s product line, which includes a total of 7 types, achieved a prescription volume of KRW 150.3 billion last year (based on pharmaceutical market research agency UBIST). Among these, ‘Tubero’ and ‘Acab’ are co-promoting with Daewon Pharmaceutical.
K-Cap is the 30th domestically produced new drug, P-CAB series for the treatment of gastroesophageal reflux disease developed by HK Innoen. K-Cap has been ranked first in the domestic peptic ulcer medicine market for four consecutive years, recording sales of KRW 132.1 billion last year (based on pharmaceutical market research company UBIST) based on its rapid efficacy, continued excellent efficacy, and safety. . Last year, the company launched an ‘oral disintegrating tablet’ product that improved the convenience of taking with a formulation that dissolves in the mouth without water.
Boryung CEO Jang Doo-hyeon said, “I hope that the case of cooperation between the two companies and the two products will become a successful model for the industry and new drug development companies.” He added, “K-New Drug will be developed through the success experience of new drugs and the clinical value-based sales and marketing capabilities of both companies.” “We look forward to further strengthening the status of our flagship product and creating new growth opportunities,” he said.
Kwak Dal-won, CEO of HK Innoen, said, “Since both companies have experience in successfully introducing popular new drugs to the market, we will maximize synergy and confirm our No. 1 position in the market. ” He added, “It will be a win-win with Boryung in the future.” “We plan to explore additional partnership opportunities as well,” he said.
#Synergy #Kdrugs #BoryungHK #Innoen #jointly #sells #KanabK #Cap
